Drug Search Results
More Filters [+]

BMS-986166

Alternative Names: bms-986166, bms986166, bms 986166
Latest Update: 2023-03-22
Latest Update Note: Clinical Trial Update

Product Description

A Novel Selective Sphingosine-1-Phosphate-1 Receptor Modulator

Mechanisms of Action: S1P1 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BMS-986166

Countries in Clinic: Australia, Austria, Canada, Germany, Poland, Spain, United States

Active Clinical Trial Count: 6

Highest Development Phases

Phase 2: Dermatitis, Atopic

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2020-004767-77

P2

Active, not recruiting

Dermatitis, Atopic

2023-01-22

IM018-010

P1

Completed

Healthy Volunteers

2022-10-15

28%

IM018-005

P2

Completed

Dermatitis, Atopic

2022-08-22

IM018-004

P1

Completed

Healthy Volunteers

2022-04-27

28%

IM018-004

P1

Completed

Healthy Volunteers

2022-04-27

28%

Recent News Events